Trump administration authorizes CIA for covert action in Venezuela - Bloomberg
Chief Medical Officer of Bicara Therapeutics (NASDAQ:BCAX), David Raben, sold 22,000 shares of common stock at a price of $18.45 on October 9, 2025, for a total of $405,900. The sale comes as the stock shows strong momentum, with a 75% gain over the past six months, though InvestingPro analysis indicates the stock is currently in overbought territory.
According to a Form 4 filing with the Securities and Exchange Commission, Raben also exercised options to acquire 22,000 shares of Bicara Therapeutics common stock at $3.7898, for a total value of $83,375. The shares were then sold on the same day. With analyst price targets ranging from $8 to $48 and the company maintaining a GOOD financial health score, InvestingPro subscribers can access deeper insights into insider trading patterns and company valuations.
Following the transaction, Raben directly owns 35,497 shares of Bicara Therapeutics.
The option exercise was related to stock options that vest in quarterly installments, with full vesting dependent on continued service. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025.
In other recent news, Bicara Therapeutics has been the focus of several analyst ratings and projections. TD Cowen reiterated its Buy rating on Bicara Therapeutics, highlighting the recent $8 billion acquisition of Merus by Genmab as a positive signal for the emerging class of EGFR bispecific antibodies, a sector in which Bicara is actively involved. Jones Trading also initiated coverage on Bicara with a Buy rating and a price target of $22.00, noting promising clinical data for Bicara’s bispecific antibody treatment for head and neck cancer. H.C. Wainwright, while maintaining a Buy rating, adjusted its price target slightly downwards to $40.00 due to higher projected long-term operating expenses. Piper Sandler initiated coverage with an Overweight rating and a $36.00 price target, citing a disconnect between market perception and expert opinions on Bicara’s ficera treatment. Additionally, in a separate development, Rice Biotech Launch Pad announced the appointment of Carolyn Ng from TPG Life Sciences to its external advisory board, expanding its expertise in biotech investments. These developments underscore the interest and varied perspectives surrounding Bicara Therapeutics in the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.